New perspectives on target intraocular pressure
The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Clement, Colin I. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion - Tachibana, Tomoyasu ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:59 ; year:2014 ; number:6 ; pages:615-626 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.survophthal.2014.04.001 |
|---|
| Katalog-ID: |
ELV017187257 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV017187257 | ||
| 003 | DE-627 | ||
| 005 | 20230625121751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.survophthal.2014.04.001 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014001000013.pica |
| 035 | |a (DE-627)ELV017187257 | ||
| 035 | |a (ELSEVIER)S0039-6257(14)00076-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.94 |2 bkl | ||
| 100 | 1 | |a Clement, Colin I. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New perspectives on target intraocular pressure |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. | ||
| 520 | |a The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. | ||
| 650 | 7 | |a intraocular pressure |2 Elsevier | |
| 650 | 7 | |a glaucoma |2 Elsevier | |
| 700 | 1 | |a Bhartiya, Shibal |4 oth | |
| 700 | 1 | |a Shaarawy, Tarek |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Tachibana, Tomoyasu ELSEVIER |t Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV005493498 |
| 773 | 1 | 8 | |g volume:59 |g year:2014 |g number:6 |g pages:615-626 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.survophthal.2014.04.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.94 |j Hals-Nasen-Ohrenheilkunde |q VZ |
| 951 | |a AR | ||
| 952 | |d 59 |j 2014 |e 6 |h 615-626 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
c i c ci cic |
|---|---|
| matchkey_str |
clementcolinibhartiyashibalshaarawytarek:2014----:eprpcieotreitac |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
44.94 |
| publishDate |
2014 |
| allfields |
10.1016/j.survophthal.2014.04.001 doi GBVA2014001000013.pica (DE-627)ELV017187257 (ELSEVIER)S0039-6257(14)00076-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.94 bkl Clement, Colin I. verfasserin aut New perspectives on target intraocular pressure 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. intraocular pressure Elsevier glaucoma Elsevier Bhartiya, Shibal oth Shaarawy, Tarek oth Enthalten in Elsevier Science Tachibana, Tomoyasu ELSEVIER Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion 2020 Amsterdam [u.a.] (DE-627)ELV005493498 volume:59 year:2014 number:6 pages:615-626 extent:12 https://doi.org/10.1016/j.survophthal.2014.04.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.94 Hals-Nasen-Ohrenheilkunde VZ AR 59 2014 6 615-626 12 045F 610 |
| spelling |
10.1016/j.survophthal.2014.04.001 doi GBVA2014001000013.pica (DE-627)ELV017187257 (ELSEVIER)S0039-6257(14)00076-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.94 bkl Clement, Colin I. verfasserin aut New perspectives on target intraocular pressure 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. intraocular pressure Elsevier glaucoma Elsevier Bhartiya, Shibal oth Shaarawy, Tarek oth Enthalten in Elsevier Science Tachibana, Tomoyasu ELSEVIER Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion 2020 Amsterdam [u.a.] (DE-627)ELV005493498 volume:59 year:2014 number:6 pages:615-626 extent:12 https://doi.org/10.1016/j.survophthal.2014.04.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.94 Hals-Nasen-Ohrenheilkunde VZ AR 59 2014 6 615-626 12 045F 610 |
| allfields_unstemmed |
10.1016/j.survophthal.2014.04.001 doi GBVA2014001000013.pica (DE-627)ELV017187257 (ELSEVIER)S0039-6257(14)00076-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.94 bkl Clement, Colin I. verfasserin aut New perspectives on target intraocular pressure 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. intraocular pressure Elsevier glaucoma Elsevier Bhartiya, Shibal oth Shaarawy, Tarek oth Enthalten in Elsevier Science Tachibana, Tomoyasu ELSEVIER Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion 2020 Amsterdam [u.a.] (DE-627)ELV005493498 volume:59 year:2014 number:6 pages:615-626 extent:12 https://doi.org/10.1016/j.survophthal.2014.04.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.94 Hals-Nasen-Ohrenheilkunde VZ AR 59 2014 6 615-626 12 045F 610 |
| allfieldsGer |
10.1016/j.survophthal.2014.04.001 doi GBVA2014001000013.pica (DE-627)ELV017187257 (ELSEVIER)S0039-6257(14)00076-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.94 bkl Clement, Colin I. verfasserin aut New perspectives on target intraocular pressure 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. intraocular pressure Elsevier glaucoma Elsevier Bhartiya, Shibal oth Shaarawy, Tarek oth Enthalten in Elsevier Science Tachibana, Tomoyasu ELSEVIER Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion 2020 Amsterdam [u.a.] (DE-627)ELV005493498 volume:59 year:2014 number:6 pages:615-626 extent:12 https://doi.org/10.1016/j.survophthal.2014.04.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.94 Hals-Nasen-Ohrenheilkunde VZ AR 59 2014 6 615-626 12 045F 610 |
| allfieldsSound |
10.1016/j.survophthal.2014.04.001 doi GBVA2014001000013.pica (DE-627)ELV017187257 (ELSEVIER)S0039-6257(14)00076-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.94 bkl Clement, Colin I. verfasserin aut New perspectives on target intraocular pressure 2014transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. intraocular pressure Elsevier glaucoma Elsevier Bhartiya, Shibal oth Shaarawy, Tarek oth Enthalten in Elsevier Science Tachibana, Tomoyasu ELSEVIER Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion 2020 Amsterdam [u.a.] (DE-627)ELV005493498 volume:59 year:2014 number:6 pages:615-626 extent:12 https://doi.org/10.1016/j.survophthal.2014.04.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.94 Hals-Nasen-Ohrenheilkunde VZ AR 59 2014 6 615-626 12 045F 610 |
| language |
English |
| source |
Enthalten in Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion Amsterdam [u.a.] volume:59 year:2014 number:6 pages:615-626 extent:12 |
| sourceStr |
Enthalten in Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion Amsterdam [u.a.] volume:59 year:2014 number:6 pages:615-626 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Hals-Nasen-Ohrenheilkunde |
| institution |
findex.gbv.de |
| topic_facet |
intraocular pressure glaucoma |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion |
| authorswithroles_txt_mv |
Clement, Colin I. @@aut@@ Bhartiya, Shibal @@oth@@ Shaarawy, Tarek @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV005493498 |
| dewey-sort |
3610 |
| id |
ELV017187257 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017187257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625121751.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.survophthal.2014.04.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014001000013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017187257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0039-6257(14)00076-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.94</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Clement, Colin I.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New perspectives on target intraocular pressure</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">intraocular pressure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">glaucoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhartiya, Shibal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shaarawy, Tarek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Tachibana, Tomoyasu ELSEVIER</subfield><subfield code="t">Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV005493498</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:615-626</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.survophthal.2014.04.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.94</subfield><subfield code="j">Hals-Nasen-Ohrenheilkunde</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2014</subfield><subfield code="e">6</subfield><subfield code="h">615-626</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Clement, Colin I. |
| spellingShingle |
Clement, Colin I. ddc 610 bkl 44.94 Elsevier intraocular pressure Elsevier glaucoma New perspectives on target intraocular pressure |
| authorStr |
Clement, Colin I. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV005493498 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.94 bkl New perspectives on target intraocular pressure intraocular pressure Elsevier glaucoma Elsevier |
| topic |
ddc 610 bkl 44.94 Elsevier intraocular pressure Elsevier glaucoma |
| topic_unstemmed |
ddc 610 bkl 44.94 Elsevier intraocular pressure Elsevier glaucoma |
| topic_browse |
ddc 610 bkl 44.94 Elsevier intraocular pressure Elsevier glaucoma |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s b sb t s ts |
| hierarchy_parent_title |
Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion |
| hierarchy_parent_id |
ELV005493498 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV005493498 |
| title |
New perspectives on target intraocular pressure |
| ctrlnum |
(DE-627)ELV017187257 (ELSEVIER)S0039-6257(14)00076-9 |
| title_full |
New perspectives on target intraocular pressure |
| author_sort |
Clement, Colin I. |
| journal |
Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion |
| journalStr |
Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
615 |
| author_browse |
Clement, Colin I. |
| container_volume |
59 |
| physical |
12 |
| class |
610 610 DE-600 610 VZ 44.94 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Clement, Colin I. |
| doi_str_mv |
10.1016/j.survophthal.2014.04.001 |
| dewey-full |
610 |
| title_sort |
new perspectives on target intraocular pressure |
| title_auth |
New perspectives on target intraocular pressure |
| abstract |
The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. |
| abstractGer |
The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. |
| abstract_unstemmed |
The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
6 |
| title_short |
New perspectives on target intraocular pressure |
| url |
https://doi.org/10.1016/j.survophthal.2014.04.001 |
| remote_bool |
true |
| author2 |
Bhartiya, Shibal Shaarawy, Tarek |
| author2Str |
Bhartiya, Shibal Shaarawy, Tarek |
| ppnlink |
ELV005493498 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.survophthal.2014.04.001 |
| up_date |
2024-07-06T21:20:33.932Z |
| _version_ |
1803866167243177984 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017187257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625121751.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.survophthal.2014.04.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014001000013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017187257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0039-6257(14)00076-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.94</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Clement, Colin I.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New perspectives on target intraocular pressure</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">intraocular pressure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">glaucoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhartiya, Shibal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shaarawy, Tarek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Tachibana, Tomoyasu ELSEVIER</subfield><subfield code="t">Supraglottic subepithelial benign mass lesions: Focus on clinical features of sialolipoma-like lesion</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV005493498</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:615-626</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.survophthal.2014.04.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.94</subfield><subfield code="j">Hals-Nasen-Ohrenheilkunde</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2014</subfield><subfield code="e">6</subfield><subfield code="h">615-626</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399988 |